Brief: Lepu Biopharma Co Says Conditional Marketing Approval Obtained In China For Puyouheng
29/09/2022 06:11
Sept 29 (Reuters) - Lepu Biopharma Co Ltd 2157.HK :
* CONDITIONAL MARKETING APPROVAL OBTAINED IN CHINA FOR
PUYOUHENG
* PUYOUHENG (PUCOTENLIMAB INJECTION) TO TREAT INOPERABLE OR
METASTATIC MELANOMA
Further company coverage: 2157.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lepu Biopharma
See all newsChina's Lepu Biopharma H1 revenue rises 12.1% on higher drug sales
Hong Kong-listed Keymed Biosciences' gastric cancer drug meets late-stage trial goals
Brief: Lepu Biopharma Reports Positive Top-Line Results From Global Phase III Trial Of CMG901 (AZD0901)
Lepu Biopharma set to jump most in 7 months on FY profit forecast
Brief: Lepu Biopharma Expects FY Net Profit Attributable